Spero Therapeutics (SPRO) Financials

Spero Therapeutics logo
$0.88 -0.02 (-2.03%)
As of 03:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Spero Therapeutics

Annual Income Statements for Spero Therapeutics

This table shows Spero Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-13 -30 -46 -42 -61 -78 -90 -47 23 -69 8.57
Consolidated Net Income / (Loss)
-13 -33 -40 -42 -61 -78 -90 -46 23 -69 8.57
Net Income / (Loss) Continuing Operations
-13 -33 -40 -42 -61 -78 -90 -47 23 -69 8.57
Total Pre-Tax Income
-13 -33 -40 -42 -61 -78 -90 -47 25 -69 8.83
Total Operating Income
-13 -33 -42 -43 -63 -79 -88 -42 21 -73 6.31
Total Gross Profit
0.00 0.34 1.98 3.97 18 9.33 18 54 104 48 67
Total Revenue
0.00 0.34 1.98 3.97 18 9.33 18 54 104 48 67
Operating Revenue
0.00 0.34 1.98 3.97 18 9.33 18 54 104 48 67
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
13 34 44 47 81 88 106 96 82 121 60
Selling, General & Admin Expense
2.20 7.22 11 13 16 21 42 36 26 24 21
Research & Development Expense
11 26 33 34 66 67 65 48 51 97 38
Impairment Charge
- - - - - - - 0.64 5.31 0.00 0.59
Restructuring Charge
- - - - - - 0.00 12 0.00 0.88 0.26
Total Other Income / (Expense), net
0.17 0.58 1.84 1.14 2.07 0.83 -1.79 -4.22 3.92 4.80 2.52
Interest & Investment Income
0.00 0.00 0.30 1.10 1.33 0.40 0.35 1.11 3.94 4.74 2.51
Other Income / (Expense), net
0.17 0.58 1.54 0.04 0.74 0.43 -0.19 0.86 -0.01 0.06 0.01
Income Tax Expense
- - - - - - - 0.00 2.60 0.00 0.26
Basic Earnings per Share
($53.11) ($95.87) ($17.82) ($2.60) ($3.35) ($3.52) ($2.91) ($1.23) $0.43 ($1.27) $0.15
Weighted Average Basic Shares Outstanding
252.81K 312.17K 2.59M 16.00M 18.16M 22.39M 30.90M 37.59M 52.70M 54.04M 56.02M
Diluted Earnings per Share
($53.11) ($95.87) ($17.82) ($2.60) ($3.35) ($3.52) ($2.91) ($1.23) $0.43 ($1.27) $0.15
Weighted Average Diluted Shares Outstanding
252.81K 312.17K 2.59M 16.00M 18.16M 22.39M 30.90M 37.59M 52.99M 54.04M 59.04M
Weighted Average Basic & Diluted Shares Outstanding
252.81K 312.17K 2.59M 16.00M 18.16M 22.39M 30.90M 52.57M 53.87M 55.90M 57.89M

Quarterly Income Statements for Spero Therapeutics

This table shows Spero Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-13 -18 -18 -20 -14 -1.70 -7.38 32 -7.20 -9.55 -44
Consolidated Net Income / (Loss)
-13 -18 -17 -21 -14 -1.70 -7.38 32 -7.20 -9.55 -44
Net Income / (Loss) Continuing Operations
-13 -18 -18 -20 -14 -1.70 -7.38 32 -7.20 -9.55 -44
Total Pre-Tax Income
-13 -18 -17 -21 -14 -1.70 -7.38 32 -7.20 -9.55 -44
Total Operating Income
-14 -19 -19 -22 -15 -2.44 -7.92 31 -7.54 -9.93 -42
Total Gross Profit
9.27 10 13 15 5.87 14 5.44 41 0.26 0.00 0.00
Total Revenue
9.27 10 13 15 5.87 14 5.44 41 0.26 0.00 0.00
Operating Revenue
9.27 10 13 15 5.87 14 5.44 41 0.26 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
23 29 32 37 21 17 13 9.89 7.80 9.93 42
Selling, General & Admin Expense
5.92 5.53 5.20 7.06 6.82 5.88 4.17 4.30 4.89 6.49 3.72
Research & Development Expense
17 24 27 29 14 11 8.60 5.59 2.91 3.43 38
Impairment Charge
0.00 - 0.00 - 0.00 - 0.59 - 0.00 - 0.00
Restructuring Charge
0.00 0.00 0.00 0.88 0.18 0.08 0.00 - 0.00 0.00 0.00
Total Other Income / (Expense), net
1.31 1.20 1.16 1.13 0.87 0.74 0.53 0.38 0.34 0.37 -2.37
Interest Expense
0.00 - - - 0.00 - 0.00 - 0.00 - 3.28
Interest & Investment Income
1.33 1.20 1.18 1.03 0.86 0.74 0.53 0.38 0.34 0.38 0.91
Other Income / (Expense), net
-0.01 0.00 -0.03 0.10 0.00 0.00 0.00 - -0.00 -0.00 0.00
Basic Earnings per Share
($0.24) ($0.33) ($0.32) ($0.38) ($0.25) ($0.03) ($0.13) $0.56 ($0.13) ($0.16) ($0.76)
Weighted Average Basic Shares Outstanding
53.52M 53.96M 54.12M 54.04M 55.38M 56.03M 56.28M 56.02M 57.28M 57.97M 58.23M
Diluted Earnings per Share
($0.24) ($0.33) ($0.32) ($0.38) ($0.25) ($0.03) ($0.13) $0.56 ($0.13) ($0.16) ($0.76)
Weighted Average Diluted Shares Outstanding
53.52M 53.96M 54.12M 54.04M 55.38M 56.03M 56.28M 59.04M 57.28M 57.97M 58.23M
Weighted Average Basic & Diluted Shares Outstanding
53.99M 54.05M 54.52M 55.90M 55.91M 56.28M 56.34M 57.89M 57.90M 58.23M 58.26M

Annual Cash Flow Statements for Spero Therapeutics

This table details how cash moves in and out of Spero Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
5.44 4.62 77 -53 -4.35 -10 27 -3.48 -33 -23 -13
Net Cash From Operating Activities
-9.61 -29 -39 -40 -50 -86 -64 -7.73 -33 -23 -13
Net Cash From Continuing Operating Activities
-9.61 -29 -39 -40 -50 -86 -64 -7.73 -33 -23 -13
Net Income / (Loss) Continuing Operations
-13 -33 -40 -42 -61 -78 -90 -46 23 -69 8.57
Consolidated Net Income / (Loss)
-13 -33 -40 -42 -61 -78 -90 -46 23 -69 8.57
Depreciation Expense
0.01 0.28 0.36 0.41 0.75 0.76 0.65 0.87 0.37 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income
3.39 4.72 -0.03 3.37 4.13 5.14 12 16 14 8.84 30
Changes in Operating Assets and Liabilities, net
0.15 -1.32 0.44 -1.07 6.78 -13 13 22 -70 36 -51
Net Cash From Investing Activities
-0.23 -0.83 -0.03 -83 30 10 7.67 34 0.00 0.00 0.00
Net Cash From Continuing Investing Activities
-0.23 -0.83 -0.03 -83 30 10 7.67 34 0.00 0.00 0.00
Net Cash From Financing Activities
0.00 34 116 70 16 131 84 -30 0.22 0.00 0.00
Net Cash From Continuing Financing Activities
15 34 116 70 16 65 84 -30 0.22 0.00 0.00
Cash Income Taxes Paid
- - - - - - - 0.00 2.21 0.00 0.00

Quarterly Cash Flow Statements for Spero Therapeutics

This table details how cash moves in and out of Spero Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
5.94 -19 13 -23 -4.00 -18 17 -8.35 16 -5.36 55
Net Cash From Operating Activities
5.94 -19 13 -23 -4.00 -18 17 -8.35 16 -5.36 -43
Net Cash From Continuing Operating Activities
5.94 -19 13 -23 -4.00 -18 17 -8.35 16 -5.36 -44
Net Income / (Loss) Continuing Operations
-13 -18 -17 -21 -14 -1.70 -7.38 32 -7.20 -9.55 -44
Consolidated Net Income / (Loss)
-13 -18 -17 -21 -14 -1.70 -7.38 32 -7.20 -9.55 -44
Non-Cash Adjustments To Reconcile Net Income
2.28 2.37 2.42 1.77 1.83 -25 1.92 25 1.34 1.05 1.21
Changes in Operating Assets and Liabilities, net
16 -3.26 27 -4.28 8.04 8.80 23 -65 22 3.15 -1.39
Net Cash From Financing Activities
0.00 - - - 0.00 - - - 0.00 - 100
Net Cash From Continuing Financing Activities
0.00 - - - 0.00 - - - 0.00 - 100

Annual Balance Sheets for Spero Therapeutics

This table presents Spero Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
14 14 93 129 106 153 171 125 182 111 69
Total Current Assets
7.30 12 92 124 95 139 158 114 131 107 67
Cash & Equivalents
4.81 10 87 34 30 85 113 109 76 53 40
Prepaid Expenses
0.41 1.25 1.83 7.48 4.82 6.06 8.83 3.38 4.18 1.91 1.63
Other Current Assets
- 0.00 - - - - - 0.00 49 49 25
Plant, Property, & Equipment, net
0.43 1.50 1.16 2.89 2.27 1.67 1.03 0.37 0.00 0.00 0.00
Total Noncurrent Assets
6.05 0.40 0.26 1.89 8.42 13 12 11 51 3.27 1.63
Other Noncurrent Operating Assets
0.09 0.21 0.21 1.66 8.40 12 12 11 4.59 3.27 1.63
Total Liabilities & Shareholders' Equity
14 14 93 129 106 153 171 125 182 111 69
Total Liabilities
6.11 7.41 8.52 13 32 21 83 49 75 64 9.90
Total Current Liabilities
6.04 6.92 8.16 12 27 14 19 22 37 49 8.87
Accounts Payable
0.88 1.14 3.47 3.60 4.15 1.16 1.10 0.62 1.38 7.31 0.69
Accrued Expenses
0.23 2.93 4.32 8.26 22 12 14 8.97 6.56 18 5.58
Current Deferred Revenue
4.75 0.14 0.14 0.23 - 0.00 1.86 10 27 22 0.26
Current Deferred & Payable Income Tax Liabilities
- - - - - - - 0.00 0.39 0.17 0.38
Other Current Liabilities
- 2.71 0.22 0.22 0.93 0.95 1.36 1.69 1.72 1.75 1.96
Total Noncurrent Liabilities
0.07 0.49 0.37 0.83 4.87 7.07 64 27 38 15 1.03
Long-Term Debt
- - - - 0.25 0.18 0.14 0.10 0.09 0.00 0.09
Other Noncurrent Operating Liabilities
0.07 - - - 4.62 6.89 55 4.96 3.83 2.55 0.94
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
7.67 -49 85 116 75 132 88 76 107 46 59
Total Preferred & Common Equity
7.67 -45 85 116 75 132 88 76 107 46 59
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
7.67 -45 85 116 75 132 88 76 107 46 59
Common Stock
17 0.00 181 254 274 410 456 490 498 506 510
Retained Earnings
-6.47 -45 -97 -139 -199 -278 -367 -414 -391 -460 -451

Quarterly Balance Sheets for Spero Therapeutics

This table presents Spero Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
107 168 150 135 78 62 54 59 53 110
Total Current Assets
102 140 122 132 75 59 52 58 52 109
Cash & Equivalents
94 82 64 76 49 31 49 56 51 108
Prepaid Expenses
5.41 3.67 3.20 2.06 1.55 1.30 1.25 1.44 0.79 1.29
Other Current Assets
- 49 51 51 24 24 0.87 0.00 0.03 0.01
Plant, Property, & Equipment, net
0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
4.84 28 28 3.53 3.00 2.72 1.85 1.41 1.18 0.80
Other Noncurrent Operating Assets
4.84 4.34 4.08 3.53 3.00 2.72 1.85 1.41 1.18 0.80
Total Liabilities & Shareholders' Equity
107 168 150 135 78 62 54 59 53 110
Total Liabilities
53 71 69 70 44 29 28 6.09 8.56 109
Total Current Liabilities
25 42 46 49 29 15 14 5.49 8.43 57
Accounts Payable
1.10 3.07 2.70 6.09 1.77 0.78 1.40 0.22 0.16 0.41
Accrued Expenses
6.56 5.38 10 15 8.19 6.73 7.81 3.14 6.11 4.04
Current Deferred Revenue
14 31 31 26 17 5.43 2.38 0.00 0.00 0.00
Current Deferred & Payable Income Tax Liabilities
2.21 0.39 0.39 0.10 0.17 0.16 0.16 0.16 0.16 0.16
Other Current Liabilities
1.71 1.73 1.73 1.74 1.80 1.84 1.90 1.97 2.00 52
Total Noncurrent Liabilities
28 30 24 21 15 14 14 0.60 0.13 52
Long-Term Debt
0.06 0.04 0.03 0.01 0.00 - - 0.09 0.09 0.00
Other Noncurrent Operating Liabilities
4.12 3.52 3.21 2.88 2.17 1.77 1.45 0.51 0.04 52
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
54 96 81 66 34 33 26 53 44 0.78
Total Preferred & Common Equity
54 96 81 66 34 33 26 53 44 0.78
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
54 96 81 66 34 33 26 53 44 0.78
Common Stock
496 500 502 504 507 508 509 511 512 513
Retained Earnings
-442 -404 -422 -439 -474 -475 -483 -458 -468 -512

Annual Metrics And Ratios for Spero Therapeutics

This table displays calculated financial ratios and metrics derived from Spero Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
4,601,241.00 4,601,241.00 14,369,182.00 18,187,488.00 19,128,146.00 27,187,489.00 32,323,617.00 51,776,053.00 52,999,317.00 54,518,165.00 56,339,295.00
DEI Adjusted Shares Outstanding
4,601,241.00 4,601,241.00 14,369,182.00 18,187,488.00 19,128,146.00 27,187,489.00 32,323,617.00 51,776,053.00 52,999,317.00 54,518,165.00 56,339,295.00
DEI Earnings Per Adjusted Shares Outstanding
-2.92 -6.50 -3.21 -2.29 -3.19 -2.88 -2.78 -0.91 0.43 -1.26 0.15
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-100.00% 0.00% 490.75% 100.40% 363.19% -49.21% 95.67% 193.10% 93.95% -53.77% 39.24%
EBITDA Growth
-2,208.01% -146.25% -23.06% -8.03% -45.21% -24.77% -11.95% 53.64% 153.97% -435.71% 108.62%
EBIT Growth
-2,650.14% -148.16% -23.12% -6.40% -46.10% -25.94% -12.05% 53.11% 151.93% -441.46% 108.62%
NOPAT Growth
-2,686.52% -149.28% -25.61% -2.58% -47.68% -25.15% -11.20% 52.03% 165.29% -366.29% 111.93%
Net Income Growth
-704.34% -148.16% -22.20% -4.45% -46.24% -28.49% -14.66% 48.29% 149.14% -400.65% 112.50%
EPS Growth
-15,074.29% -80.51% 81.41% 85.41% -28.85% -5.07% 17.33% 57.73% 134.96% -395.35% 111.81%
Operating Cash Flow Growth
-1,403.21% -201.41% -35.06% -1.31% -26.23% -71.68% 25.07% 87.99% -326.79% 28.95% 46.15%
Free Cash Flow Firm Growth
-547.14% -187.32% -60.17% -6.24% -11.78% -85.47% 102.51% -3,290.29% 18.36% 68.64% -39.79%
Invested Capital Growth
0.00% 0.00% 40.53% 117.30% -1,852.91% 173.54% -1,191.60% 42.95% 192.66% -122.08% 378.55%
Revenue Q/Q Growth
-100.00% 0.00% 0.00% 21.40% 13.33% -17.26% 4.81% 507.23% 33.57% -54.93% 64.74%
EBITDA Q/Q Growth
-914.87% 0.00% 0.00% 5.85% -29.07% 8.57% -11.09% 58.45% 2,028.07% -6,569.61% 113.53%
EBIT Q/Q Growth
-2,738.49% 0.00% 0.00% 6.47% -29.04% 8.06% -11.01% 57.97% 3,679.40% -6,335.56% 113.53%
NOPAT Q/Q Growth
-6,069.21% 0.00% 0.00% 6.38% -30.57% 8.22% -10.98% 55.87% 981.00% -4,551.51% 118.70%
Net Income Q/Q Growth
-2,400.82% 0.00% 0.00% 7.28% -30.91% 7.56% -13.47% 54.68% 1,513.01% -2,051.78% 119.55%
EPS Q/Q Growth
-48,181.82% 0.00% 0.00% -103.51% -31.37% 18.14% -12.79% 60.70% -2.27% -1,687.50% 118.99%
Operating Cash Flow Q/Q Growth
-837.08% 1.80% -9.94% -1.98% -8.36% 1.13% -20.54% 90.28% -213.85% -33.69% 54.38%
Free Cash Flow Firm Q/Q Growth
-551.26% 0.00% 0.00% 0.00% 6.11% -1.91% 104.45% 9.96% -322.05% 54.14% 9.03%
Invested Capital Q/Q Growth
-100.00% 0.00% 0.00% 107.26% -1,175.97% -7.33% -409.72% -85.25% 176.51% 37.18% 185.20%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
0.00% -9,660.30% -2,012.43% -1,084.85% -340.10% -835.50% -478.01% -75.60% 21.04% -152.78% 9.46%
Operating Margin
0.00% -9,916.72% -2,108.64% -1,079.32% -344.13% -847.94% -481.87% -78.86% 20.70% -152.91% 9.45%
EBIT Margin
0.00% -9,743.58% -2,030.77% -1,078.24% -340.10% -843.31% -482.92% -77.25% 20.68% -152.78% 9.46%
Profit (Net Income) Margin
0.00% -9,743.58% -2,015.46% -1,050.48% -331.65% -839.01% -491.65% -86.74% 21.98% -142.91% 12.83%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 99.64% 100.00% 100.00% 98.65% 89.77% 100.00% 97.05%
Interest Burden Percent
100.00% 100.00% 99.25% 97.43% 97.87% 99.49% 101.81% 113.83% 118.34% 93.54% 139.74%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10.23% 0.00% 2.95%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -430.05% 101.44%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -403.39% 96.19%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 340.43% -85.13%
Return on Equity (ROE)
0.00% 66.28% -223.39% -41.49% -63.99% -75.77% -81.47% -56.53% 24.95% -89.62% 16.31%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% -7,950.78% 0.00% -1,278.71% 0.00% 0.00% -145.00% 0.00% -103.39%
Operating Return on Assets (OROA)
0.00% -237.01% -74.94% -38.44% -53.15% -60.63% -54.33% -27.94% 13.98% -50.05% 7.04%
Return on Assets (ROA)
0.00% -237.01% -74.38% -37.45% -51.83% -60.32% -55.32% -31.37% 14.85% -46.81% 9.55%
Return on Common Equity (ROCE)
0.00% 61.15% -245.00% -41.35% -63.87% -75.77% -81.47% -56.53% 24.95% -89.62% 16.31%
Return on Equity Simple (ROE_SIMPLE)
0.00% 71.83% -47.15% -36.07% -81.70% -59.29% -101.66% -61.13% 21.34% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-9.33 -23 -29 -30 -44 -55 -62 -30 19 -51 6.13
NOPAT Margin
0.00% -6,941.70% -1,476.05% -755.53% -240.89% -593.56% -337.31% -55.20% 18.58% -107.04% 9.17%
Net Nonoperating Expense Percent (NNEP)
0.00% 41.49% -50.72% -11.54% -16.91% -21.96% -20.64% -13.22% 3.80% -26.66% 5.25%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - 18.03% -111.34% 10.37%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 2,156.12% 547.75% 324.94% 84.86% 229.80% 228.42% 68.18% 24.62% 49.41% 31.70%
R&D to Revenue
0.00% 7,860.60% 1,660.89% 854.39% 358.06% 718.15% 353.45% 88.94% 49.57% 201.67% 57.58%
Operating Expenses to Revenue
0.00% 10,016.72% 2,208.64% 1,179.32% 442.91% 947.94% 581.87% 180.05% 79.30% 252.91% 90.55%
Earnings before Interest and Taxes (EBIT)
-13 -33 -40 -43 -62 -79 -88 -41 21 -73 6.32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-13 -32 -40 -43 -62 -78 -87 -40 22 -73 6.32
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 2.00 0.97 2.47 3.99 5.86 1.18 0.73 1.22 2.22
Price to Tangible Book Value (P/TBV)
0.00 0.00 2.00 0.97 2.47 3.99 5.86 1.18 0.73 1.22 2.22
Price to Revenue (P/Rev)
0.00 26.54 85.31 28.20 10.01 56.50 28.35 1.67 0.75 1.17 1.97
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.42 0.00 15.31
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 29.27% 0.00% 6.53%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 75.40 0.00 0.00 0.05 0.00 4.83
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 41.39 0.00 5.56 42.92 20.34 0.00 0.02 0.07 1.36
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.00 14.41
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.00 14.41
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.00 14.87
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 217.57 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
0.00 -0.92 -1.18 -1.01 -1.04 -1.01 -1.24 -1.55 -1.01 -0.84 -0.89
Leverage Ratio
0.00 -0.28 3.00 1.11 1.23 1.26 1.47 1.80 1.68 1.91 1.71
Compound Leverage Factor
0.00 -0.28 2.98 1.08 1.21 1.25 1.50 2.05 1.99 1.79 2.39
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.33% 0.13% 0.16% 0.13% 0.08% 0.00% 0.15%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.33% 0.13% 0.16% 0.13% 0.08% 0.00% 0.15%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 7.73% 0.42% 0.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% 92.27% 99.58% 99.69% 99.67% 99.86% 99.84% 99.87% 99.92% 100.00% 99.85%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01
Net Debt to EBITDA
0.00 0.00 0.00 0.00 1.31 1.63 1.68 2.69 -3.49 0.00 -6.36
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01
Debt to NOPAT
0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.01
Net Debt to NOPAT
0.00 0.00 0.00 0.00 1.85 2.29 2.38 3.69 -3.95 0.00 -6.56
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.01
Altman Z-Score
0.00 -11.26 10.12 3.58 -0.12 11.58 0.13 -3.32 -0.81 -6.42 1.08
Noncontrolling Interest Sharing Ratio
0.00% 7.73% -9.67% 0.35% 0.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.00 1.72 11.29 10.08 3.58 9.70 8.46 5.25 3.53 2.19 7.59
Quick Ratio
0.00 1.54 10.82 9.40 3.37 9.22 7.98 5.09 2.10 1.14 4.54
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-6.70 -19 -31 -33 -37 -68 1.71 -54 -44 -14 -19
Operating Cash Flow to CapEx
-4,141.38% -3,489.04% -144,855.56% -1,626.64% -15,929.94% -54,695.54% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.88 -8.80 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -33.17 -1.25 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -33.17 -1.25 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.02 0.04 0.04 0.16 0.07 0.11 0.36 0.68 0.33 0.74
Accounts Receivable Turnover
0.00 1.10 3.01 5.72 4.52 1.43 4.58 28.73 78.95 20.72 42.92
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.22 1.49 1.96 7.11 4.73 13.55 76.77 560.98 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 331.22 121.27 63.82 80.83 256.05 79.68 12.70 4.62 17.61 8.50
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 331.22 121.27 63.82 80.83 256.05 79.68 12.70 4.62 17.61 8.50
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
0.00 -4.00 -2.38 0.41 -7.22 5.31 -58 -33 31 -6.77 19
Invested Capital Turnover
0.00 -0.17 -0.62 -4.03 -5.40 -9.76 -0.69 -1.18 -85.45 4.02 11.06
Increase / (Decrease) in Invested Capital
-2.63 -4.00 1.62 2.79 -7.63 13 -63 25 64 -37 26
Enterprise Value (EV)
0.00 -5.23 82 -3.23 102 400 371 -19 1.66 3.26 91
Market Capitalization
8.89 8.89 169 112 184 527 518 90 78 56 131
Book Value per Share
$0.00 ($9.88) $5.89 $6.35 $3.90 $4.86 $2.73 $1.47 $2.02 $0.85 $1.05
Tangible Book Value per Share
$0.00 ($9.88) $5.89 $6.35 $3.90 $4.86 $2.73 $1.47 $2.02 $0.85 $1.05
Total Capital
0.00 -49 85 116 75 132 88 76 107 46 59
Total Debt
0.00 0.00 0.00 0.00 0.25 0.18 0.14 0.10 0.09 0.00 0.09
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.25 0.18 0.14 0.10 0.09 0.00 0.09
Net Debt
0.00 -10 -87 -115 -82 -127 -146 -109 -76 -53 -40
Capital Expenditures (CapEx)
0.23 0.83 0.03 2.44 0.31 0.16 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -5.36 -3.39 -3.54 -13 -2.10 -7.20 -17 18 5.31 18
Debt-free Net Working Capital (DFNWC)
0.00 4.95 84 112 69 125 139 92 94 58 58
Net Working Capital (NWC)
0.00 4.95 84 112 69 125 139 92 94 58 58
Net Nonoperating Expense (NNE)
3.82 9.39 11 12 17 23 28 17 -3.52 17 -2.44
Net Nonoperating Obligations (NNO)
0.00 45 -87 -115 -82 -127 -146 -109 -76 -53 -40
Total Depreciation and Amortization (D&A)
0.01 0.28 0.36 -0.26 0.00 0.73 0.90 0.88 0.37 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% -1,600.30% -171.10% -89.31% -72.37% -22.55% -39.44% -32.12% 17.08% 11.07% 27.17%
Debt-free Net Working Capital to Revenue
0.00% 1,478.81% 4,239.62% 2,821.51% 374.26% 1,337.64% 762.50% 171.79% 90.63% 121.31% 87.45%
Net Working Capital to Revenue
0.00% 1,478.81% 4,239.62% 2,821.51% 374.26% 1,337.64% 762.50% 171.79% 90.63% 121.31% 87.45%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($53.11) ($95.87) ($17.82) ($2.60) ($3.35) ($3.52) ($2.91) ($1.23) $0.43 ($1.27) $0.15
Adjusted Weighted Average Basic Shares Outstanding
252.81K 312.17K 14.37M 17.22M 20.33M 29.50M 32.76M 37.59M 52.70M 54.04M 56.02M
Adjusted Diluted Earnings per Share
($53.11) ($95.87) ($17.82) ($2.60) ($3.35) ($3.52) ($2.91) ($1.23) $0.43 ($1.27) $0.15
Adjusted Weighted Average Diluted Shares Outstanding
252.81K 312.17K 14.37M 17.22M 20.33M 29.50M 32.76M 37.59M 52.99M 54.04M 59.04M
Adjusted Basic & Diluted Earnings per Share
($53.11) ($95.87) ($17.82) ($2.60) ($3.35) ($3.52) ($2.91) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
252.81K 312.17K 2.59M 16.00M 18.16M 22.39M 30.90M 52.57M 53.87M 55.90M 57.89M
Normalized Net Operating Profit after Tax (NOPAT)
-9.33 -23 -29 -30 -44 -55 -62 -21 24 -51 6.95
Normalized NOPAT Margin
0.00% -6,941.70% -1,476.05% -755.53% -240.89% -593.56% -337.31% -39.16% 23.17% -105.76% 10.40%
Pre Tax Income Margin
0.00% -9,743.58% -2,015.46% -1,050.48% -332.87% -839.01% -491.65% -87.93% 24.48% -142.91% 13.22%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -45.44 -6.68 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -31.74 -4.78 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -45.44 -6.68 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -31.74 -4.78 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% -2.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% -11.91% -3.15% -0.26% -1.22% -0.28% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Spero Therapeutics

This table displays calculated financial ratios and metrics derived from Spero Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
53,869,139.00 53,986,639.00 54,049,139.00 54,518,165.00 55,900,641.00 55,910,641.00 56,275,225.00 56,339,295.00 57,891,493.00 57,901,493.00 58,234,827.00
DEI Adjusted Shares Outstanding
53,869,139.00 53,986,639.00 54,049,139.00 54,518,165.00 55,900,641.00 55,910,641.00 56,275,225.00 56,339,295.00 57,891,493.00 57,901,493.00 58,234,827.00
DEI Earnings Per Adjusted Shares Outstanding
-0.24 -0.33 -0.33 -0.37 -0.25 -0.03 -0.13 0.56 -0.12 -0.17 -0.76
Growth Metrics
- - - - - - - - - - -
Revenue Growth
347.90% 275.44% -47.12% -79.54% -36.61% 39.15% -59.60% 174.51% -95.61% -100.00% -100.00%
EBITDA Growth
0.85% -49.03% -914.11% -142.76% -5.24% 87.20% 57.50% 245.22% 48.82% -306.93% -429.59%
EBIT Growth
1.64% -47.80% -857.77% -142.79% -5.24% 87.20% 57.50% 245.22% 48.82% -306.93% -429.59%
NOPAT Growth
1.72% -47.87% -861.38% -130.32% -5.36% 87.18% 57.42% 306.51% 48.83% -306.14% -429.47%
Net Income Growth
4.50% -49.92% -435.01% -140.80% -9.45% 90.48% 56.95% 250.90% 48.05% -461.88% -499.81%
EPS Growth
4.00% -43.48% -433.33% -139.18% -4.17% 90.91% 59.38% 247.37% 48.00% -433.33% -484.62%
Operating Cash Flow Growth
146.20% -0.97% -19.81% -33.77% -167.40% 5.61% 36.50% 64.31% 496.40% 69.73% -344.56%
Free Cash Flow Firm Growth
-45.11% -1,294.45% -302.90% 263.62% 134.06% 125.68% 113.74% -73.92% -191.84% -91.47% 858.32%
Invested Capital Growth
144.74% 174.44% 73.11% -122.08% -207.54% -90.39% -105.40% 378.55% 79.41% -496.51% -384.35%
Revenue Q/Q Growth
-87.40% 10.04% 32.09% 11.69% -60.95% 141.56% -61.65% 658.86% -99.38% -100.00% 0.00%
EBITDA Q/Q Growth
-127.67% -36.17% 2.30% -16.15% 31.89% 83.44% -224.34% 496.83% -124.01% -31.70% -322.12%
EBIT Q/Q Growth
-127.70% -36.18% 2.31% -16.15% 31.89% 83.44% -224.34% 496.83% -124.01% -31.70% -322.12%
NOPAT Q/Q Growth
-119.52% -36.33% 2.46% -16.85% 32.19% 83.41% -223.90% 666.75% -116.80% -31.68% -322.25%
Net Income Q/Q Growth
-124.75% -40.99% 4.00% -21.82% 33.62% 87.74% -334.24% 526.98% -122.85% -32.61% -363.55%
EPS Q/Q Growth
-124.74% -37.50% 3.03% -18.75% 34.21% 88.00% -333.33% 530.77% -123.21% -23.08% -375.00%
Operating Cash Flow Q/Q Growth
133.95% -415.66% 168.09% -283.35% 82.90% -342.10% 198.47% -147.93% 289.97% -133.76% -695.65%
Free Cash Flow Firm Q/Q Growth
-306.22% 3.55% 20.45% 152.49% -15.44% -27.29% -57.44% -0.32% -397.75% 106.75% 4,680.73%
Invested Capital Q/Q Growth
-54.27% 21.28% -163.36% 37.18% -122.78% 110.84% -1,453.86% 185.20% -116.47% -108.73% -1,553.76%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00%
EBITDA Margin
-151.03% -186.90% -138.24% -143.75% -250.77% -17.20% -145.42% 76.05% -2,922.09% 0.00% 0.00%
Operating Margin
-150.88% -186.93% -138.04% -144.41% -250.78% -17.22% -145.46% 76.05% -2,921.71% 0.00% 0.00%
EBIT Margin
-151.03% -186.92% -138.24% -143.75% -250.77% -17.20% -145.42% 76.05% -2,922.09% 0.00% 0.00%
Profit (Net Income) Margin
-136.71% -175.17% -127.31% -138.85% -236.06% -11.98% -135.65% 76.33% -2,791.86% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 98.34% 101.41% 100.00% 100.00% 100.00% 99.18% 100.00% 100.00% 100.00%
Interest Burden Percent
90.52% 93.71% 93.65% 95.25% 94.13% 69.67% 93.28% 101.20% 95.54% 96.20% 105.65%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% -406.15% 0.00% -62.87% 0.00% 841.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% -397.35% 0.00% -62.89% 0.00% 840.75% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 335.34% 0.00% 52.55% 0.00% -744.15% 0.00% 0.00% 0.00%
Return on Equity (ROE)
29.06% 25.81% 5.89% -70.81% -107.28% -10.32% -95.29% 96.85% 35.12% 19.17% -216.41%
Cash Return on Invested Capital (CROIC)
-184.01% -142.83% 0.00% 0.00% 0.00% -267.08% 0.00% -103.39% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-119.62% -178.02% -121.49% -47.09% -91.11% -7.88% -62.29% 56.61% -2,615.24% 0.00% 0.00%
Return on Assets (ROA)
-108.28% -166.83% -111.88% -45.48% -85.77% -5.49% -58.10% 56.82% -2,498.69% 0.00% 0.00%
Return on Common Equity (ROCE)
29.06% 25.81% 5.89% -70.81% -107.28% -10.32% -95.29% 96.85% 35.12% 19.17% -216.41%
Return on Equity Simple (ROE_SIMPLE)
24.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-9.79 -13 -13 -15 -10 -1.71 -5.54 31 -5.28 -6.95 -29
NOPAT Margin
-105.62% -130.85% -96.63% -101.09% -175.55% -12.06% -101.82% 76.05% -2,045.19% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-3.23% -6.40% -4.86% -8.80% -5.42% 0.02% -2.95% 0.25% -3.67% -6.36% -19.09%
Return On Investment Capital (ROIC_SIMPLE)
-10.16% -16.57% -19.86% -32.97% -30.50% -5.21% -20.91% 53.13% -9.95% -15.69% -3,756.61%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
63.85% 54.26% 38.59% 46.90% 116.17% 41.43% 76.70% 10.41% 1,894.19% 0.00% 0.00%
R&D to Revenue
187.03% 232.67% 199.45% 191.68% 231.63% 75.21% 157.98% 13.54% 1,127.52% 0.00% 0.00%
Operating Expenses to Revenue
250.88% 286.93% 238.04% 244.41% 350.78% 117.22% 245.46% 23.95% 3,021.71% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-14 -19 -19 -22 -15 -2.44 -7.91 31 -7.54 -9.93 -42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-14 -19 -19 -22 -15 -2.44 -7.91 31 -7.54 -9.93 -42
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.96 0.87 1.11 1.22 1.19 4.94 3.99 2.22 2.56 2.89 90.22
Price to Tangible Book Value (P/TBV)
0.96 0.87 1.11 1.22 1.19 4.94 3.99 2.22 2.56 2.89 90.22
Price to Revenue (P/Rev)
0.83 0.59 0.68 1.17 0.90 3.34 2.61 1.97 2.21 2.72 1.70
Price to Earnings (P/E)
3.96 4.02 24.69 0.00 0.00 0.00 0.00 15.31 8.89 17.33 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
25.26% 24.87% 4.05% 0.00% 0.00% 0.00% 0.00% 6.53% 11.25% 5.77% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.74 0.39 0.00 0.00 0.00 80.14 0.00 4.83 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.09 0.06 0.00 0.07 0.00 2.70 1.41 1.36 1.30 1.64 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.47 0.43 0.00 0.00 0.00 0.00 0.00 14.41 5.88 12.83 0.00
Enterprise Value to EBIT (EV/EBIT)
0.48 0.43 0.00 0.00 0.00 0.00 0.00 14.41 5.88 12.83 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.53 0.43 0.00 0.00 0.00 0.00 0.00 14.87 5.98 12.83 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.97 3.95 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 60.61 5.47 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.11 -1.04 -1.43 -0.84 -1.01 -0.84 -1.36 -0.89 -1.21 -1.06 -5.74
Leverage Ratio
1.74 1.84 2.03 1.91 1.89 1.87 2.06 1.71 1.58 1.49 6.02
Compound Leverage Factor
1.57 1.72 1.90 1.82 1.78 1.30 1.92 1.73 1.51 1.43 6.36
Debt to Total Capital
0.04% 0.03% 0.02% 0.00% 0.00% 0.00% 0.00% 0.15% 0.17% 0.21% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.04% 0.03% 0.02% 0.00% 0.00% 0.00% 0.00% 0.15% 0.17% 0.21% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
99.96% 99.97% 99.98% 100.00% 100.00% 100.00% 100.00% 99.85% 99.83% 99.79% 100.00%
Debt to EBITDA
0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.00
Net Debt to EBITDA
-3.75 -4.05 69.41 0.00 0.00 0.00 0.00 -6.36 -4.15 -8.41 0.00
Long-Term Debt to EBITDA
0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.00
Debt to NOPAT
0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.00
Net Debt to NOPAT
-4.21 -4.08 69.09 0.00 0.00 0.00 0.00 -6.56 -4.22 -8.41 0.00
Long-Term Debt to NOPAT
0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.00
Altman Z-Score
-1.50 -2.35 -2.85 -4.88 -7.33 -5.88 -9.06 2.28 4.16 -2.19 -6.44
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
3.35 2.68 2.68 2.19 2.56 3.97 3.83 7.59 10.50 6.12 1.92
Quick Ratio
2.09 1.50 1.61 1.14 1.70 2.25 3.68 4.54 10.23 6.02 1.89
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-55 -53 -42 22 19 14 5.81 5.79 -17 1.16 56
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 16.99
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -13.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -13.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.79 0.95 0.88 0.33 0.36 0.46 0.43 0.74 0.90 0.82 0.51
Accounts Receivable Turnover
32.25 34.73 37.45 20.72 15.68 13.50 18.92 42.92 171.87 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
860.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
11.32 10.51 9.75 17.61 23.27 27.03 19.29 8.50 2.12 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
11.32 10.51 9.75 17.61 23.27 27.03 19.29 8.50 2.12 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
14 17 -11 -6.77 -15 1.63 -22 19 -3.10 -6.48 -107
Invested Capital Turnover
-12.82 -40.58 -4.19 4.02 -84.36 5.21 -2.47 11.06 -6.73 -19.40 -0.64
Increase / (Decrease) in Invested Capital
45 40 29 -37 -29 -15 -11 26 12 -8.11 -85
Enterprise Value (EV)
10 6.68 -3.85 3.26 -8.64 131 57 91 79 77 -37
Market Capitalization
93 70 72 56 40 162 106 131 135 128 70
Book Value per Share
$1.79 $1.49 $1.21 $0.85 $0.60 $0.59 $0.47 $1.05 $0.91 $0.76 $0.01
Tangible Book Value per Share
$1.79 $1.49 $1.21 $0.85 $0.60 $0.59 $0.47 $1.05 $0.91 $0.76 $0.01
Total Capital
96 81 66 46 34 33 26 59 53 44 0.78
Total Debt
0.04 0.03 0.01 0.00 0.00 0.00 0.00 0.09 0.09 0.09 0.00
Total Long-Term Debt
0.04 0.03 0.01 0.00 0.00 0.00 0.00 0.09 0.09 0.09 0.00
Net Debt
-82 -64 -76 -53 -49 -31 -49 -40 -56 -51 -108
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
16 13 6.24 5.31 -3.33 13 -9.94 18 -4.01 -7.62 -56
Debt-free Net Working Capital (DFNWC)
98 77 83 58 46 44 39 58 52 43 52
Net Working Capital (NWC)
98 77 83 58 46 44 39 58 52 43 52
Net Nonoperating Expense (NNE)
2.88 4.52 4.13 5.68 3.55 -0.01 1.84 -0.12 1.93 2.60 15
Net Nonoperating Obligations (NNO)
-82 -64 -76 -53 -49 -31 -49 -40 -56 -51 -108
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
14.47% 11.02% 5.86% 11.07% -7.46% 27.30% -24.52% 27.17% -6.55% -16.21% -133.95%
Debt-free Net Working Capital to Revenue
88.61% 64.65% 77.53% 121.31% 102.19% 91.52% 95.38% 87.45% 85.19% 91.83% 125.78%
Net Working Capital to Revenue
88.61% 64.65% 77.53% 121.31% 102.19% 91.52% 95.38% 87.45% 85.19% 91.83% 125.78%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.24) ($0.33) ($0.32) ($0.38) ($0.25) ($0.03) ($0.13) $0.56 ($0.13) ($0.16) ($0.76)
Adjusted Weighted Average Basic Shares Outstanding
53.52M 53.96M 54.12M 54.04M 55.38M 56.03M 56.28M 56.02M 57.28M 57.97M 58.23M
Adjusted Diluted Earnings per Share
($0.24) ($0.33) ($0.32) ($0.38) ($0.25) ($0.03) ($0.13) $0.56 ($0.13) ($0.16) ($0.76)
Adjusted Weighted Average Diluted Shares Outstanding
53.52M 53.96M 54.12M 54.04M 55.38M 56.03M 56.28M 59.04M 57.28M 57.97M 58.23M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
53.99M 54.05M 54.52M 55.90M 55.91M 56.28M 56.34M 57.89M 57.90M 58.23M 58.26M
Normalized Net Operating Profit after Tax (NOPAT)
-9.79 -13 -13 -15 -10 -1.65 -5.13 22 -5.28 -6.95 -29
Normalized NOPAT Margin
-105.62% -130.85% -96.63% -97.01% -173.46% -11.65% -94.27% 53.23% -2,045.19% 0.00% 0.00%
Pre Tax Income Margin
-136.71% -175.17% -129.46% -136.92% -236.06% -11.98% -135.65% 76.96% -2,791.86% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -12.79
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -8.95
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -12.79
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -8.95
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Spero Therapeutics’ latest results show a company with a meaningful cash cushion but continued dependence on its pipeline and potential future financing or partnership activity. As of June 30, 2026, Spero held $50.8 million in cash and equivalents, down from $56.1 million at the end of the first quarter and $93.8 million in the third quarter of 2023.

Revenue has become highly volatile. Quarterly revenue was $41.3 million in the fourth quarter of 2025, fell to $258,000 in the first quarter of 2026 and was zero in the second quarter. The latest quarter produced a $9.6 million net loss, compared with a $7.2 million loss in Q1 2026. While operating expenses declined to $9.9 million from $20.6 million in Q1 2024 and $32.1 million in Q3 2024, the company remains unprofitable and generates no consistent operating revenue.

  • Liquidity remains adequate in the near term: Spero had $50.8 million of cash against $8.6 million of total liabilities at June 30, 2026. Based on the latest quarter’s $5.4 million operating cash outflow, the company has a substantial liquidity buffer, although quarterly cash usage can vary significantly.
  • Low debt burden: Long-term debt was only $91,000, limiting interest expense and reducing balance-sheet leverage.
  • Strong current ratio: Current assets of $51.6 million compared with current liabilities of $8.4 million indicate substantial coverage of near-term obligations.
  • Operating expenses have generally declined: Q2 2026 operating expenses of $9.9 million were considerably below the elevated expense levels reported during 2024, suggesting cost-control efforts have reduced the company’s quarterly spending base.
  • Interest and investment income provides support: Investment income contributed $377,000 in Q2 2026, partially offsetting operating losses and helping the company earn a return on its cash balance.
  • Cash flow remains inconsistent: Operating cash flow was positive by $15.9 million in Q1 2026 but turned negative by $5.4 million in Q2. The Q1 benefit was driven heavily by a $21.7 million favorable change in operating assets and liabilities rather than recurring profitability.
  • Balance-sheet liabilities have improved substantially: Total liabilities declined to $8.6 million in Q2 2026 from $69.7 million in Q3 2024, but this improvement coincided with the disappearance of deferred revenue and should not be interpreted as evidence of sustainable earnings growth.
  • Revenue momentum has deteriorated: Reported revenue fell from $14.2 million in Q2 2025 and $41.3 million in Q4 2025 to zero in Q2 2026. The lack of recurring revenue makes the company’s financial performance heavily dependent on product milestones, licensing activity or other nonrecurring transactions.
  • Spero continues to post operating losses: Q2 2026 operating income was negative $9.9 million, and retained earnings were negative $467.8 million. The company has not demonstrated a path to sustained profitability in the data provided.
  • Cash is being depleted over the longer term: Cash declined from $167.7 million in total assets and $82.3 million of cash at Q1 2024 to $50.8 million of cash at Q2 2026. Continued operating losses could eventually require additional capital, potentially creating dilution risk for shareholders.

Overall, Spero’s balance sheet is currently stronger than its income statement: debt is minimal, liquidity is still meaningful and expenses are lower than in prior periods. However, the sharp decline in revenue, recurring net losses and inconsistent operating cash flow remain significant risks. Investors should focus on whether the company can restore recurring revenue or secure non-dilutive funding before its cash balance declines materially further.

11/18/26 03:52 PM ETAI Generated. May Contain Errors.

Spero Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Spero Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Spero Therapeutics' net income appears to be on an upward trend, with a most recent value of $8.57 million in 2025, compared with -$13.15 million in 2015. The previous period was -$68.57 million in 2024. Check out Spero Therapeutics' forecast to explore projected trends and price targets.

Spero Therapeutics' total operating income in 2025 was $6.31 million, based on the following breakdown:
  • Total Gross Profit: $66.80 million
  • Total Operating Expenses: $60.49 million

Over the last 10 years, Spero Therapeutics' total revenue changed from $0.00 in 2015 to $66.80 million in 2025, a change of 6,680,200,000.0%.

In the past 12 quarters, Spero Therapeutics' cash and equivalents has ranged from $31.19 million in Q2 2025 to $107.93 million in Q3 2026, and is currently $107.93 million as of their latest financial filing in Q3 2026.

Spero Therapeutics had total debt of $91 thousand at the end of 2025, compared with none in 2024, and none in 2015.

Over the last 10 years, Spero Therapeutics' book value per share changed from 0.00 in 2015 to 1.05 in 2025, a change of 104.8%.



Financial statements for NASDAQ:SPRO last updated on 11/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners